ArticleJSES international2025
The role of medical comorbidities in rotator cuff retear after arthroscopic repair: a TriNetX database review of 98,844 patients.
Article in JSES international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Early postoperative functional outcomes and influencing factors in patients with rotator cuff injury].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Article
- GLP‑1 receptor agonist therapy and 2‑year structural outcomes after arthroscopic rotator cuff repair in type 2 diabetes.BMC musculoskeletal disorders · 2026Article
- Postoperative angiotensin II receptor blocker use is associated with reduced 2-year reoperation rates in male patients undergoing arthroscopic rotator cuff repair.JSES international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Arthroscopic rotator cuff repair (ARCR) is the most common form of operative intervention utilized in the treatment of rotator cuff tears. Retear rates following ARCR have been reported to range from 7% to 94%. This study was undertaken to better understand the effects of various medical comorbidities and age on rotator cuff retear risk following ARCR. Methods: The TriNetX US Collaborative Network was queried for all patients treated with ARCR from 2013 to 2022 with recurrence of rotator cuff tear within 1 year. Cohorts were defined by inclusion of medical comorbidities at time of ARCR including hypertension, hyperlipidemia, chronic ischemic heart disease, type 2 diabetes mellitus, smoking history, and chronic kidney disease. Patient age groups in 10-year increments were also examined. Propensity score matching was performed for comorbid groups to adjust for age and comorbidities. Relative risk was calculated for each comorbidity and age group. Results: There were a total of 98,844 patients who underwent ARCR for complete rotator cuff tear from 2012 to 2023 with an overall retear percentage of 16.3% within 1 year of surgery. Hypertension, hyperlipidemia, and smoking history were significant risk factors of retear after propensity score matching. Chronic ischemic heart disease, chronic kidney disease, and type 2 diabetes mellitus were not significant risk factors of retear after propensity score matching. It was also noted that relative risk of retear increased as patient age increased; patients aged 81-90 having the highest likelihood of retear (relative risk: 1.206), with a retear rate of 19.6%. Conclusion: Medical comorbidities and advanced age can increase the risk of rotator cuff retear following ARCR. Understanding how these common comorbidities affect retear rate following ARCR can better inform orthopedic surgeons of potential risks and optimize postoperative outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.